

variable sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively).

D2  
Cont

24. (Amended) The method of claim 23 wherein the anti-B7.1 antibody binds the same epitope as antibody 16C10, which has the variable sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively).

D3

32. (Twice Amended) The method of claim 21 wherein the antibody is a primatized antibody having the variable sequences of an anti-B7.1 antibody selected from the group consisting of 7C10, which has the variable sequences shown in Figures 8a and 8b (amino acid sequences of SEQ ID NOs. 1-2 and 3-4, respectively); 7B6, which has the variable sequences shown in Figures 9a and 9b (amino acid sequences of SEQ ID NOs. 5-6 and 7-8, respectively); and 16C10, which has the variable sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12, respectively).

33. (Amended) The method of claim 21 wherein the anti-B7.1 antibody is a monoclonal antibody having a human gamma 4 constant domain.

Please add the following new claim:

D4

37. The method of claim 32 wherein the antibody is a primatized antibody having the variable sequences of antibody 16C10 shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12, respectively).

#### REMARKS

This amendment is responsive to the Office Action mailed on October 11, 2002. Claims 21, 23, 24, 32, and 33 are amended, and claim 22 is canceled, such that the claims are directed to the elected method wherein the the recited anti-B7 antibody is an anti-B7.1 antibody. Claim 32 is amended to remove typographical errors. New claim 37 recites a primatized antibody having the variable sequences of antibody 16C10, support for which is